Autobio and Pushkang have reached strategic cooperation

On December 14, 2022, Autobio and Pushkang signed a strategic cooperation agreement in Zhengzhou, and the two sides will again open in-depth cooperation in the field of blood coagulation testing. Since the cooperation between the two sides in 2021, AutoBio has carried out multi scenario verification and promotion on the small full-automatic coagulation analyzer HMC560 developed by Pushkang, which has won unanimous praise from end customers, and also laid a solid market foundation for the use of the high-throughput full-automatic coagulation detection systems HMC800 and HMC680 in the first-class hospitals.

The two sides firmly believe that the further and in-depth cooperation at the strategic level will give full play to the advantages of the channel sales of the products of PSK Bio centrifuge microfluidic technology and Autobio, share resources and unite strengths, and jointly promote the application and development of new coagulation detection technologies in the Chinese class hospital market. Through deepening cooperation, Autobio can provide overall solutions for coagulation projects in terms of microfluidic coagulation, high-throughput coagulation equipment, coagulation lines and compatible reagents to meet the diversified needs of laboratories.

About Autobio:

Autobio Diagnostics Co., Ltd (Hereinafter called Autobio) was founded in 1998, headquartered in National Eco & Tech Zone, Zhengzhou.

Autobio specialized in R & D, production, marketing and service of clinical diagnostic products, especially covering immunoassay, microbiology and biochemistry fields. Meanwhile, Autobio is also actively planning the developments in the field of molecular diagnostics and provides a comprehensive solutions for medical laboratories. Autobio was listed on Shanghai Stock Exchange on September 1st, 2016, which is the first IVD manufacturer listed on the main board in Shanghai, China. In 2019, Autobio’s revenue achieved USD412 millions, a year-on-year increase of 38.85%; in 2020, Autobio’s revenue achieved USD459 millions.

About Pushkang: 

Zhejiang Pushkang Biotechnology Co., Ltd. was founded in 2014 by Dr.Yu Bo, coming back from America, is a high & new tech enterprise specialized in In Vitro Diagnosis(IVD), adhering to the concept of "Let health testing at your touch", taking advantage of the world leading centrifugal microfluidic technology platform, focusing on the detection of urgent diseases & chronic disease management, mainly researching and developing new POCT diagnostic system for thrombus and hemostasis function testing, while developing new immune, biochemical series of centrifugal microfluidic diagnostic systems as well as supporting reagents.

Zhejiang Pushkang is committed to providing all-round advanced and convenient microfluidic technology products for medical institutions, researching and developing new diagnostic systems suiting for emergency departments, small and medium-sized hospitals, community primary hospitals, clinical departments and mobile medical, serving the fast growing China’s medical market.

The main business scope of Zhejiang Pushkang is the R&D, production and sales of 6840 medical devices (class I, II, III in vitro diagnostic reagents and clinical analytical instruments). After years of development, now we have established and completed 3 microfluidic technolog platforms focusing on coagulation, chemiluminescence and biochemistry, and have developed corresponding detection instruments, microfluidic disc chip and supporting reagents on the basis of the platforms. In strict compliance with the relevant laws and regulations of medical devices, we have obtained the EU ISO13485 certification of quality management system and CE product certification, built a good quality system, and kept the system running continuously and effectively. We are leading in microfluidic disc chip technology in China and have completely independent intellectual property rights.

At present, we have more than 300 employees, whose majors including biomedical engineering, electronic information engineering, microfluidic technology, mechanical automation, software engineering, etc., forming a professional and reasonably-structured R &D team with high professional quality and strong innovation ability.

The company has now applied for more than 70 international and domestic patents, has authorized 26 invention patents, including 7 U.S. patents.